Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAR T-cell therapy-related gastrointestinal toxicity presents with symptoms like abdominal pain and diarrhea, occurring 1.5 to eight months post-treatment. Histologic examination reveals a graft versus host disease-like pattern, with epithelial apoptosis and a paucity of B cells and plasma cells, necessitating careful differentiation from mimics like graft versus host disease and infection.
Summary Long-read sequencing, combined with transcriptomic profiling and functional assays, resolved six out of seven cases of unresolved inherited metabolic diseases, revealing pathogenic variations outside coding regions. This highlights the importance of considering non-coding variants in genetic diagnoses. Additionally, a study on diffuse large B-cell lymphoma (DLBCL) using single-cell RNA sequencing and ATAC-seq revealed extensive intratumoral heterogeneity and subtype-specific gene-expression programs, suggesting a dynamic ecosystem rather than a static diagnostic category. Editors: Donna E. Hansel, MD, PhD, division head of
A study on the Hologic Genius digital diagnostic system (GDDS) for AI-assisted cervical cytology screening identified technical issues during validation. While most errors were manageable and did not compromise patient safety, the study emphasized the importance of standardized slide preparation and workflow planning for successful implementation. Additionally, a review by the College of American Pathologists found that CAP accreditation frameworks are broadly applicable to machine learning-based methods in molecular oncology testing, providing a robust framework for validation and oversight.
Summary Q. as long as digitization of glass slides occurs in the technical component (TC) process, regardless of whether or not the digitization of glass slides and pathologist review are performed remotely? Is a lab in compliance to bill the digital codes if a pathologist sits in the office next to the lab? Q. Do regulatory agencies still support sodium citrate platelet counts? What is the CAP’s standing? Q. Is secretory change in endometrial hyperplasia acceptable in the absence of
PathGroup, a clinical laboratory, partnered with Labgnostic to automate proficiency testing order entry and result delivery. LabgnosticPT, an application from Labgnostic, automates the PT process, integrating with laboratory information systems for seamless order and result transmission. This automation significantly reduces administrative time, allowing PathGroup staff to focus more on patient-centered work.
Vitestro raised $70 million in Series B financing to advance its Aletta robotic phlebotomy device. The funding will support product development, manufacturing, clinical expansion, and commercial readiness for the Aletta, which uses imaging, robotics, and AI for blood collection.
